A novel alternative for pyrogen detection based on a transgenic cell line

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• Pyrogens are critical contaminants affecting parenteral drug safety, necessitating reliable detection methods.
• Existing in vivo rabbit pyrogen tests face pressure for replacement by in vitro alternatives, aligning with the 3Rs principle (reduction, replacement, refinement).
• Regulatory agencies worldwide are increasingly prioritizing in vitro pyrogen testing.

Purpose of the Study:

• To develop and validate a novel in vitro pyrogen detection assay.
• To establish an alternative to traditional animal-based pyrogen testing for parenteral drugs and biologicals.

Main Methods:

• Utilized a THP-1 monocyte cell line, engineered with a luciferase reporter gene regulated by NF-κB (a key inflammatory signaling molecule).
• Quantified pyrogen presence by measuring fluorescence signal intensity, indicating NF-κB activation.
• Assessed the test's performance across various pyrogen types, biological product categories, and cell passage numbers.

Main Results:

• The assay demonstrated quantitative and sensitive detection of both endotoxin (lipopolysaccharide) and non-endotoxin pyrogens (e.g., lipoteichoic acid, zymosan).
• The test showed excellent stability over 39 cell passages and applicability to diverse biologicals, including vaccines and therapeutic proteins.
• Achieved high reproducibility (80-95%) and diagnostic accuracy, with sensitivity of 89.9% and specificity of 90.9%.

Conclusions:

• The developed NF-κB-based in vitro assay offers a robust, sensitive, and reproducible alternative for pyrogen detection.
• This novel method supports the regulatory drive to replace in vivo pyrogen testing with safer and more ethical in vitro approaches.
• The test is suitable for routine pyrogen screening in a wide range of parenteral products.